Skip to content
Protocol GuideFact-checked March 2026

Ipamorelin & CJC-1295: The Safe Stack for Growth Hormone Optimisation

Ipamorelin and CJC-1295 (without DAC) are the two most selective and physiologically appropriate growth hormone secretagogue peptides available. Used together, they stimulate GH secretion more strongly than either pathway alone, timed to the body's natural nocturnal GH secretion pattern. This...

Evidence strength

Level 4

Case series / Animal studies

Peer-reviewed refs

3

Reading time

13 min

Key Takeaways

  • Ipamorelin is the most selective GHRP available — it raises GH without cortisol, prolactin, or ACTH elevation that other GHRPs (GHRP-2, GHRP-6, Hexarelin) produce.
  • CJC-1295 (no DAC) and Ipamorelin activate different receptor types; in human studies, combined GHRH plus GH-releasing peptide stimulation is synergistic — a markedly larger GH pulse than either alone.
  • Fasted pre-sleep injection is critical — glucose/insulin can reduce GHRH-stimulated GH release by up to 70%. Always inject 2+ hours after last meal.
  • WADA prohibits both peptides. Active cancer and diabetic retinopathy are absolute contraindications. IGF-1 elevation requires monitoring in susceptible individuals.

Why GH Declines and Why It Matters

Growth hormone secretion follows a predictable age-related decline. Peak GH output occurs in the second decade of life. By age 40, total GH secretion has declined by approximately 50%. By age 60, it may be 80% below youthful levels.

The consequences extend beyond muscle and fat composition. Growth hormone plays roles in:

  • Sleep architecture: GH secretion is tightly coupled to slow-wave sleep; GH decline contributes to reduced sleep quality with age
  • Tissue repair: The majority of soft tissue repair occurs during GH-stimulated sleep windows
  • Cognitive function: GH receptors in the hippocampus and frontal cortex influence memory and executive function
  • Immune function: GH modulates thymic activity and natural killer cell function

The pharmaceutical approach to GH decline is direct recombinant HGH injection — expensive, requiring prescription, and producing supraphysiological GH levels with attendant side effects. The Ipamorelin + CJC-1295 approach is different: it amplifies the body's own pulsatile GH secretion rather than replacing it.

The Two Receptor Pathways

The pituitary's GH-secreting somatotrophs have two distinct receptor types relevant to secretagogue peptides:

GHRH receptor (activated by CJC-1295): When stimulated, increases cAMP and prepares the somatotroph's secretory granules for release. Think of this as "loading the gun" — building up the GH available to be released.

GHSR (Ghrelin receptor) (activated by Ipamorelin): When stimulated, triggers the actual release of pre-formed GH secretory granules. Think of this as "pulling the trigger."

Activating both pathways simultaneously — which is what the combined stack does — is synergistic: in human studies, co-infusion of GHRH with a GH-releasing peptide produces marked stimulation of pulsatile GH secretion, well beyond either peptide alone. That synergy is blunted by older age and more abdominal-visceral fat.

[2] This synergism is the mechanistic foundation of the stack.

Ipamorelin vs Other GHRPs

GHRPGH StimulationCortisolProlactinReceptor Selectivity
GHRP-2StrongYes (+75%)YesNon-selective
GHRP-6StrongYes (+60%)YesNon-selective
HexarelinVery strongYes (+100%)YesRapid desensitisation
IpamorelinModerateNoNoHighly selective

Ipamorelin produces less absolute GH stimulation than GHRP-2 or Hexarelin — but it does so without the cortisol and prolactin elevation that make the others problematic for sustained use. Over a 12-16 week cycle, the cumulative advantage of clean GH stimulation without cortisol suppression of its benefits is substantial.

[1]

Why Pre-Sleep Fasted Injection Is Critical

The body's largest natural GH pulse is tied to sleep onset and slow-wave sleep. In men, this sleep-onset pulse is generally the major — or even the only — episode of active GH secretion in the day, and the amount of GH released rises in step with the amount of slow-wave sleep. Both decline together with age.

[3]

Injecting Ipamorelin + CJC-1295 30-60 minutes before sleep amplifies this natural pulse at the physiologically correct time. The fasted state is mandatory: insulin (elevated after meals) suppresses GH secretion by increasing somatostatin tone. Studies show post-meal insulin can reduce GHRH-stimulated GH release by up to 70%.

Rule: Last meal at least 2-3 hours before injection. No protein shakes or carbohydrates after injection until the morning. Water and electrolytes are fine.

Standard Protocol

Nightly injection (30-60 min before sleep, fasted):

  • Ipamorelin: 100-200mcg subcutaneous
  • CJC-1295 (no DAC): 100mcg subcutaneous
  • Inject both simultaneously, any subcutaneous site

Cycle: 12-16 weeks on, 4-8 weeks off

Reconstitution:

  • Ipamorelin 5mg vial + 2.5ml bacteriostatic water = 2mg/ml. 200mcg dose = 0.1ml
  • CJC-1295 5mg vial + 2.5ml bacteriostatic water = 2mg/ml. 100mcg dose = 0.05ml

Adding to the Wolverine Stack

The Ipamorelin + CJC-1295 combination adds a third layer to the Wolverine Stack:

  1. BPC-157 — local tissue repair environment
  2. TB-500 — systemic repair cell mobilisation
  3. Ipamorelin + CJC-1295 — elevated GH during sleep amplifies the repair processes that layers 1 and 2 have initiated

BPC-157 specifically upregulates GH receptors in healing tissue — so the elevated GH produced by Ipamorelin + CJC-1295 has more sensitive targets to work on. The interaction is mechanistically sound and consistently reported as additive in the practitioner community.

Related Substances

Scientific References

  1. [1]
    Raun K, et al.. Ipamorelin, a new growth-hormone-releasing peptide — European Journal of Endocrinology (1998)Oxford 4
    PMID 9849822
  2. [2]
    Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men — American Journal of Physiology. Endocrinology and Metabolism (2009)Oxford 2b
    PMID 19240251
  3. [3]
    Van Cauter E, Copinschi G. Interrelationships between growth hormone and sleep — Growth Hormone & IGF Research (2000)Oxford 5
    PMID 10984255

Follow us on Google Search

Add BiohackingHub as a preferred source to see more of our research in Google results.

Ad slot available · 728×90Advertise here

Related protocols

Partner with BiohackingHub

Editorial placements, sponsorships, and product features for evidence-minded brands.

Partnership opportunities →